{"id":"cor-1","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"1-5%","effect":"Pneumonitis"}]},"_chembl":{"chemblId":"CHEMBL4741106","moleculeType":"Unknown","molecularWeight":"260.34"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, COR-1 prevents the interaction between PD-1 and its ligands, thereby releasing the inhibition on T cells and enhancing the immune response against cancer cells.","oneSentence":"COR-1 is a monoclonal antibody targeting the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:28:54.041Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT01391507","phase":"PHASE2","title":"Pilot Study of COR-1 in Heart Failure","status":"COMPLETED","sponsor":"Corimmun GmbH","startDate":"2011-10","conditions":"Cardiomyopathy, Dilated","enrollment":36},{"nctId":"NCT01043146","phase":"PHASE1","title":"Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide","status":"COMPLETED","sponsor":"Corimmun GmbH","startDate":"2009-10","conditions":"Heart Failure","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":295,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["cyclic peptide"],"phase":"phase_2","status":"active","brandName":"COR-1","genericName":"COR-1","companyName":"Corimmun GmbH","companyId":"corimmun-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"COR-1 is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}